Adverse impact of venous thromboembolism on patients with cancer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalSeminars in Thrombosis and Hemostasis
Issue number3
StatePublished - 2014


  • anticoagulation
  • bleeding
  • cancer
  • chemotherapy
  • survival
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)


Dive into the research topics of 'Adverse impact of venous thromboembolism on patients with cancer'. Together they form a unique fingerprint.

Cite this